Current peptide vaccine and immunotherapy approaches against Alzheimer's disease

Peptide vaccines and immunotherapies against aggregating proteins involved in the pathogenesis and progression of Alzheimer's disease (AD)-the beta-amyloid peptide (A beta) and tau-are promising therapeutic avenues against AD. Two decades of effort has led to the controversial United States Food and Drug Administration (FDA) approval of the monoclonal antibody Aducanumab (Aduhelm), which has subsequentially sparked the revival and expedited review of promising monoclonal antibody immunotherapies that target A beta. In this review, we explore the development of A beta and tau peptide vaccines and immunotherapies with monoclonal antibodies in clinical trials against AD.

Automated summary

In this review, the development of A β and tau peptide vaccines and immunotherapies with monoclonal antibodies in clinical trials against AD is explored. The revival and expedited review of promising monoclonal antibody immunotherapies targeting A β has attracted significant attention.